Furtado RHM, et al. - Given that reduction in the risk of major adverse cardiovascular events (MACE) could be achieved with the use of sodium glucose transporter-2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) and a history of atherosclerotic cardiovascular (CV) disease (ASCVD), researchers examined whether SGLT2i therapy may offer even greater benefits to patients with prior myocardial infarction (MI) because of their baseline risk. In the DECLARE TIMI-58 trial, 17,160 patients with T2DM and either established ASCVD (n=6,974) or multiple risk factors (n=10,186) were randomly allocated to dapagliflozin or placebo treatment groups. Observations suggested a high risk of MACE and CV death/hospitalization for heart failure among patients with T2DM and prior MI. Thus, a robust reduction in the risk of both composite outcomes in these patients could be achieved using dapagliflozin.